BioInvent and Immusol to collaborate on antibody therapeutic for macular degeneration

04-Apr-2006

BioInvent International AB and Immusol, Inc. announced a collaboration for the development of a fully human n-CoDeR® antibody for the treatment of age related macular degeneration (AMD) and other ophthalmic disorders. Macular degeneration is characterised by abnormal and uncontrolled vessel growth in the eye.

The collaboration will bring together a rich portfolio of expertise in the area therapeutic antibody research and development. Immusol will contribute its expertise in ophthalmology and intellectual property rights covering the use of antagonists against a biological target identified to play an important role in the underlying pathological process of AMD. BioInvent will contribute its knowledge and experience in angiogenesis, immunology and therapeutic antibody discovery and development. Under the terms of the collaboration, the parties will share costs and revenues in further development and commercialization.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances